Abstract
Background: S-isomer (S) pantoprazole is known to be more effective and less dependent on cytochrome 2C19 than R-isomer (R)-pantoprazole. Aim: The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. Methods: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S-pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. Results: Sixty-seven patients in the S-pantoprazole group (52 male, mean age 51 years) and 62 in the pantoprazole group (61 male, mean age 50 years) were analyzed per protocol. The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). After treatment, individual and overall gastroesophageal reflux disease (GERD) symptoms and esophagitis improved compared with baseline inflammation in both groups. Intergroup differences in symptoms and endoscopic healing were not significant. Conclusion: The efficacy and safety of 20 mg S-pantoprazole were comparable to those of 40 mg pantoprazole for treatment of reflux esophagitis and symptomatic improvement of GERD.
| Original language | English |
|---|---|
| Pages (from-to) | 3189-3194 |
| Number of pages | 6 |
| Journal | Digestive Diseases and Sciences |
| Volume | 57 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2012 Dec 1 |
Keywords
- Efficacy
- Enantiomer
- Pantoprazole
- Proton pump inhibitor
- Racemate
ASJC Scopus subject areas
- Gastroenterology
- Physiology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Cho, Y. K., Choi, M. G., Bak, Y.-T., Rhee, P. L., Kim, S. G., Jung, H. Y., & Seol, S. Y. (2012). Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial. Digestive Diseases and Sciences, 57(12), 3189-3194. https://doi.org/10.1007/s10620-012-2297-y
Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial. / Cho, Yu Kyung; Choi, Myung Gyu; Bak, Young-Tae et al.
In: Digestive Diseases and Sciences, Vol. 57, No. 12, 01.12.2012, p. 3189-3194.
Research output: Contribution to journal › Article › peer-review
Cho, YK, Choi, MG, Bak, Y-T, Rhee, PL, Kim, SG, Jung, HY & Seol, SY 2012, 'Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial', Digestive Diseases and Sciences, vol. 57, no. 12, pp. 3189-3194. https://doi.org/10.1007/s10620-012-2297-y
Cho YK, Choi MG, Bak YT, Rhee PL, Kim SG, Jung HY et al. Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial. Digestive Diseases and Sciences. 2012 Dec 1;57(12):3189-3194. doi: 10.1007/s10620-012-2297-y
Cho, Yu Kyung ; Choi, Myung Gyu ; Bak, Young-Tae et al. / Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis : A randomized, double-blind comparative trial. In: Digestive Diseases and Sciences. 2012 ; Vol. 57, No. 12. pp. 3189-3194.
@article{d1b5e37a5c004270982e7e341478239d,
title = "Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: A randomized, double-blind comparative trial",
abstract = "Background: S-isomer (S) pantoprazole is known to be more effective and less dependent on cytochrome 2C19 than R-isomer (R)-pantoprazole. Aim: The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. Methods: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S-pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. Results: Sixty-seven patients in the S-pantoprazole group (52 male, mean age 51 years) and 62 in the pantoprazole group (61 male, mean age 50 years) were analyzed per protocol. The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). After treatment, individual and overall gastroesophageal reflux disease (GERD) symptoms and esophagitis improved compared with baseline inflammation in both groups. Intergroup differences in symptoms and endoscopic healing were not significant. Conclusion: The efficacy and safety of 20 mg S-pantoprazole were comparable to those of 40 mg pantoprazole for treatment of reflux esophagitis and symptomatic improvement of GERD.",
keywords = "Efficacy, Enantiomer, Pantoprazole, Proton pump inhibitor, Racemate",
author = "Cho, {Yu Kyung} and Choi, {Myung Gyu} and Young-Tae Bak and Rhee, {Poong Lyul} and Kim, {Sang Gyun} and Jung, {Hoon Yong} and Seol, {Sang Young}",
year = "2012",
month = dec,
day = "1",
doi = "10.1007/s10620-012-2297-y",
language = "English",
volume = "57",
pages = "3189--3194",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "12",
}
TY - JOUR
T1 - Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis
T2 - A randomized, double-blind comparative trial
AU - Cho, Yu Kyung
AU - Choi, Myung Gyu
AU - Bak, Young-Tae
AU - Rhee, Poong Lyul
AU - Kim, Sang Gyun
AU - Jung, Hoon Yong
AU - Seol, Sang Young
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Background: S-isomer (S) pantoprazole is known to be more effective and less dependent on cytochrome 2C19 than R-isomer (R)-pantoprazole. Aim: The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. Methods: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S-pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. Results: Sixty-seven patients in the S-pantoprazole group (52 male, mean age 51 years) and 62 in the pantoprazole group (61 male, mean age 50 years) were analyzed per protocol. The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). After treatment, individual and overall gastroesophageal reflux disease (GERD) symptoms and esophagitis improved compared with baseline inflammation in both groups. Intergroup differences in symptoms and endoscopic healing were not significant. Conclusion: The efficacy and safety of 20 mg S-pantoprazole were comparable to those of 40 mg pantoprazole for treatment of reflux esophagitis and symptomatic improvement of GERD.
AB - Background: S-isomer (S) pantoprazole is known to be more effective and less dependent on cytochrome 2C19 than R-isomer (R)-pantoprazole. Aim: The purpose of this study was to compare the efficacy and safety of S-pantoprazole 20 mg versus pantoprazole 40 mg for treatment of reflux esophagitis. Methods: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S-pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. Results: Sixty-seven patients in the S-pantoprazole group (52 male, mean age 51 years) and 62 in the pantoprazole group (61 male, mean age 50 years) were analyzed per protocol. The healing rate of reflux esophagitis was 85 % at 4 weeks and 94 % at 8 weeks in the S-pantoprazole group, which did not differ from those in the pantoprazole group (84 and 97 %, respectively). After treatment, individual and overall gastroesophageal reflux disease (GERD) symptoms and esophagitis improved compared with baseline inflammation in both groups. Intergroup differences in symptoms and endoscopic healing were not significant. Conclusion: The efficacy and safety of 20 mg S-pantoprazole were comparable to those of 40 mg pantoprazole for treatment of reflux esophagitis and symptomatic improvement of GERD.
KW - Efficacy
KW - Enantiomer
KW - Pantoprazole
KW - Proton pump inhibitor
KW - Racemate
UR - http://www.scopus.com/inward/record.url?scp=84871638481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871638481&partnerID=8YFLogxK
U2 - 10.1007/s10620-012-2297-y
DO - 10.1007/s10620-012-2297-y
M3 - Article
C2 - 22772870
AN - SCOPUS:84871638481
SN - 0163-2116
VL - 57
SP - 3189
EP - 3194
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 12
ER -
